Oregon's Psilocybin Program Shows Promise in New Study

Oregon's experiment with legal magic mushrooms is working better than even skeptics expected.

A new study tracking almost 350 people who took psilocybin at state-licensed centers found that most participants described their experience as beneficial. More than half ranked it among the most meaningful experiences of their entire lives.

The research, published Wednesday in JAMA Network Open, represents the first rigorous look at what happens when psychedelics move from research labs into the real world. Oregon launched the nation's first nonmedical psilocybin program three years ago, allowing adults over 21 to take the drug under supervision without a prescription or medical referral.

Dr. Todd Korthuis from Oregon Health & Science University admitted he started out skeptical about giving people psychedelics outside tightly controlled medical settings. "The data has swayed me," he told NPR. "These results are very reassuring."

Safety concerns turned out to be minimal. Only four participants experienced what researchers classified as "serious adverse reactions," and the overall rate of problems matched what doctors typically see with other psychiatric interventions.

Participants came to the centers for different reasons: curiosity, self-improvement, mental health struggles, and trauma. The average dose was about 30 milligrams, slightly higher than what clinical trials typically use. More than half said their mental health symptoms improved afterward.

Other scientists expressed surprise at how well the program performed. Balázs Szigeti, a clinical data scientist at UC San Francisco, noted that the program operated in a business environment with far less medical oversight than research studies. "To see that the whole thing did not blow up is definitely good news for psilocybin," he said.

The study does have limitations. Participants were mostly white, college-educated, and affluent, with about a third earning over $200,000 annually. These demographics mirror the broader population visiting Oregon's licensed centers, which cluster around Portland.

Albert Garcia-Romeu from Johns Hopkins noted he's personally heard from Oregon participants who struggled after their experiences. "We really can't generalize based on this study that it's going to be this safe and look this way for everyone," he cautioned.

Why This Inspires

What makes Oregon's program remarkable is how it offers an alternative path for psychedelic access. While pharmaceutical companies race to win FDA approval for psilocybin as a prescription treatment for depression, Oregon voters chose a different route in 2020. Their model trusts adults to make their own choices about consciousness and healing, with professional guidance but without medical gatekeeping.

The results suggest this trust was well-placed. More than 20,000 people have gone through the program since it launched, and serious problems remain rare.

Korthuis believes the drug's benefits extend beyond treating single conditions. "Sometimes people come in for one thing and come out with three others," he explained, describing how psilocybin helps people revisit multiple issues in their lives.

Colorado has since launched its own psychedelic program, and researchers plan to track many more Oregon participants through their ongoing initiative called OPEN.

A bold experiment in healing is proving that sometimes the best medicine comes with a little more freedom and a lot more trust.